within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L01E_ProteinKinaseInhibitors.L01EF01_Palbociclib;

model Palbociclib
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.46,
    Cl = 1.758333333333333e-05,
    adminDuration = 600,
    adminMass = 125 / 1000000,
    adminCount = 1,
    Vd = 3.24,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.016,
    Tlag = 25.02,
    Vdp = 1.51,
    k12 = 2.4305555555555558e-05,
    k21 = 2.4305555555555558e-05);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Palbociclib</td></tr><tr><td>ATC code:</td><td>L01EF01</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>125</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>3240</td><td>L</td></tr>
    <tr><td>clearance:</td><td>63.3</td><td>L/hr</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Palbociclib is an oral, selective inhibitor of cyclin-dependent kinases 4 and 6 (CDK4/6), used primarily in the treatment of hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. It is an FDA- and EMA-approved antineoplastic agent administered in combination with endocrine therapy.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult advanced breast cancer patients, both female and male (predominantly female), mean age ~57 years, oral dosing.</p><h4>References</h4><ol><li><p>Royer, B, et al., &amp; Schmitt, A (2021). Population Pharmacokinetics of Palbociclib in aReal-World Situation. <i>Pharmaceuticals (Basel, Switzerland)</i> 14(3) –. DOI:<a href=\"https://doi.org/10.3390/ph14030181\">10.3390/ph14030181</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33668400/\">https://pubmed.ncbi.nlm.nih.gov/33668400</a></p></li><li><p>Yu, Y, et al., &amp; Wang, D (2020). Palbociclib (PD-0332991) pharmacokinetics in subjects with impaired renal function. <i>Cancer chemotherapy and pharmacology</i> 86(6) 701–710. DOI:<a href=\"https://doi.org/10.1007/s00280-020-04163-4\">10.1007/s00280-020-04163-4</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/33037918/\">https://pubmed.ncbi.nlm.nih.gov/33037918</a></p></li><li><p>Panetta, JC, et al., &amp; Stewart, CF (2024). Population Pharmacokinetic and Pharmacodynamic Study of Palbociclib in Children and Young Adults with Recurrent, Progressive, or Refractory Brain Tumors. <i>Pharmaceutics</i> 16(12) –. DOI:<a href=\"https://doi.org/10.3390/pharmaceutics16121528\">10.3390/pharmaceutics16121528</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/39771507/\">https://pubmed.ncbi.nlm.nih.gov/39771507</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.L.L01EF01 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Palbociclib;
